RxDoctor Payments Data

Kelley McIntyre, MD

Internal Medicine · Louisville, KYNPI 1497710693

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $37,281 of the $47,906 with a category attached, or 77.8%. Novo Nordisk accounts for 98.8% of it on its own, with 11 other manufacturers making up the rest. Among internal medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$47,906in general payments, 2019–2025

Across 90 payments — averaging $532.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$47K
  • Lilly USA, LLC$129
  • Axsome Therapeutics, Inc.$109
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$106
  • AbbVie$59
  • Alkermes, Inc.$38
  • plus $149 from 6 others

What the payments were for

  • Speaking & faculty fees$37,28178%
  • Travel & lodging$7,34915%
  • Food & beverage$3,2677%
  • Education$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,906 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$9,922
Medicare patients
38
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$44,225
EliquisApixaban11$10,094
SynthroidLevothyroxine Sodium30$1,590
Losartan Potassium89$862
Rosuvastatin Calcium58$849
Potassium Chloride26$742
Atorvastatin Calcium65$599
Levothyroxine Sodium53$576
Buspirone Hcl16$520
Np ThyroidThyroid,pork12$488
Cyclobenzaprine Hcl11$359
Montelukast Sodium23$314
Duloxetine Hcl24$311
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid33$293
Amlodipine Besylate68$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$47,316$44,22536 claims
AbbVieSynthroid$59$1,59030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →